Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.
Frequency of patients treated with biotechnological and JAK inhibitors (in bold) and the number of treatment courses for each molecule (in italic) in this VEXAS cohort.
| Biotechnological agent | n (%) |
|---|---|
| Anti-TNF | 8 (11.6) |
| Adalimumab | 2 |
| Etanercept | 6 |
| Infliximab | 1 |
| Anti-IL-1 | 12 (17.4) |
| Anakinra | 11 |
| Canakinumab | 2 |
| Anti-IL-6 | 12 (17.4) |
| Tocilizumab | 12 |
| Sarilumab | 1 |
| Rituximab | 3 (4.3) |
| Abatacept | 1 (1.5) |
| JAK inhibitors | 15 (21.7) |
| Ruxolitinib | 7 |
| Tofacitinib | 3 |
| Filgotinib | 3 |
| Baricitinib | 2 |
| Upadacitinib | 2 |
